|
Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer. |
|
|
Consulting or Advisory Role - Astellas Pharma; Dendreon; GlaxoSmithKline; Merck |
Research Funding - Acceleron Pharma; AstraZeneca; Bristol-Myers Squibb; Dendreon; GlaxoSmithKline; Lilly; Merck |
Patents, Royalties, Other Intellectual Property - patent pending |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Sanofi |
|
|
No Relationships to Disclose |
|
|
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - eviti |
|
|
Employment - Visible Health |
Leadership - UrologyMatch |
Honoraria - Genomic Health |
Consulting or Advisory Role - Genomic Health |
Travel, Accommodations, Expenses - Genomic Health; Visible Health |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Endo Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
Employment - Foundation Medicine |
Stock and Other Ownership Interests - Foundation Medicine |
|
|
No Relationships to Disclose |
|
|
Patents, Royalties, Other Intellectual Property - Patent Pending |